This comes a few months after it raised a $10 million Series B round of fundingRead more...
With $25.2 billion, the amount invested was down 52% year-to-year
A couple of months ago, a Rock Health report showed investments into digital health companies falling to a two-year low, a sign of a slowdown from the highs of the pandemic. And now it looks like the entire ecosystem is experiencing that same problem.
With $25.2 billion in August, global venture funding fell to its lowest point since exactly two years prior, when there was $22.4 billion invested in August 2020, according to data from Crunchbase News. The number is down 52% from $52.9 billion in August of 2021, and down 10% from the $28.1 billion raised in July of this year.
This is the second month in a row where VC dollars have dropped, after they fell 33% in July; the total drop in the last two months has been 40%.
When broken down by stage, the Crunchbase analysis found that it was the later stage companies that are being affected the most; in fact, early stage funding actually rose 25% from the previous month, growing from $9.3 billion to $11.6 billion. Year-to-year, early stage funding is down 35%, however.
The round that saw the least impact were Series A rounds, which Crunchbase found were flat year-to-year, while Series B round fell by 55% from August 2021, and Series C rounds were down 77%. Month-to-month, A and B rounds both rose, while funding to C rounds fell.
"This year started out quite well for Series B and C rounds, with more funding raised compared to 2021 in the earlier months. But then from March onward, Series C fundings trended well below 2021 amounts, and Series B fundings followed suit and were down more dramatically in July and August 2022," Crunchbase wrote.
Besides digital health, another sector that has seen a big drop are public cloud software companies, with funding down around 55% from August 2021.
(Image source: healthline.com)
Support VatorNews by Donating
Read more from our "Trends and news" series
The company uses AI to generate a model for each company based on their dataRead more...
The two companies will combine forces to recommend alternative drugs to health systemsRead more...